Last reviewed · How we verify

Dina Youssef Attia — Portfolio Competitive Intelligence Brief

Dina Youssef Attia pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Benzocaine oral gel 20% Benzocaine oral gel 20% marketed Local anesthetic Voltage-gated sodium channels Pain management / Oral care

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams Maternity Hospital · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Aligarh Muslim University · 1 shared drug class
  4. Atlantic Health System · 1 shared drug class
  5. Aultman Health Foundation · 1 shared drug class
  6. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  7. Bagcilar Training and Research Hospital · 1 shared drug class
  8. Abant Izzet Baysal University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dina Youssef Attia:

Cite this brief

Drug Landscape (2026). Dina Youssef Attia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dina-youssef-attia. Accessed 2026-05-16.

Related